Management of dyslipidemia in adults with diabetes

Diabetes Care

Volumn 21, Issue 1, 1998, Pages 160-178

  Haffner, Steven M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ANTILIPEMIC AGENT; BILE ACID; CHLORPROPAMIDE; CHOLESTEROL; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLIBENCLAMIDE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; METFORMIN; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; RESIN; SIMVASTATIN; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG MIXTURE; DYSLIPIDEMIA; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KINESIOTHERAPY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHABDOMYOLYSIS;

EID: 0031964325     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.1.160     Document Type: Review

References (235)

1. Kannel WB, McGee DL: Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study. Diabetes Care 2:120-126, 1979
2. Wingard DL, Barrett-Connor E: Heart disease and diabetes. In Diabetes in America. 2nd ed. Harris MI, Ed. Washington, DC, U.S. Govt. Printing Office, 1995, p. 429-448
3. Pyörälä K, Laakso M, Uusitupa M: Diabetes and atherosclerosis: an epidemiologic view (Review). Diabetes Metab Rev 3:463-524, 1987
4. Bierman EL: Atherogenesis in diabetes (Review). Arterioscler Thromb 12:647-656, 1992
5. Brownlee M: Glycation products and the pathogenesis of diabetic complications. Diabetes Care 15:1835-1843, 1992
6. Vlassara H, Bucala R: Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Diabetes 45:S65-S66, 1996
7. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325:836-842, 1991
8. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR, Baynes JW, Lyons TJ: Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 91:2470-2478, 1993
9. Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T, Dohi K, Makita Z, Vlassara H, Bucala R: Immunohistochemical localization of advanced glycosylation endproducts in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 143:1649-1656, 1993
10. Nishimoto S, Oohara T, Sakai M, Igaki N, Masuta S, Nakamichi T, Maeda Y, Hata F, Kitamura Y, Matsumoto S: Collagen-glycation in the aorta: a developmental factor of aging and atherosclerosis. Kobe J Med Sci 34:179-187, 1988
11. Bucala R, Makita Z, Koschinsky T, Cerami A: Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 91:9441-9445, 1993
12. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, Vlassara H: Modification of LDL by advanced glycosylation endproducts contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91:9441-9445, 1994
13. Steinberg D, Parthasarathy S, Carew TE, Khou JC, Witztum JL: Beyond cholesterol: modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med 320:913-924, 1989
14. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL: Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 260:2864-2871, 1988
15. Diabetes Control and Complications Trial Research Group (DCCT): The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
16. Jarrett RJ: Type 2 (non-insulin-dependent) diabetes mellitus and coronary heart disease: chicken, egg or neither? Diabetologia 26:99-102, 1984
17. West KM, Ahuja MM, Bennett PH, Czyzyk A, De Acosta OM, Fuller JH, Grab B, Grabauskas V, Jarrett RJ, Kosaka K, Keen H, Krolweski AS, Miki E, Schliack V, Teuscher A, Watkins PJ, Stober JA: The role of circulating glucose and triglyceride concentrations and their interactions with other "risk factors" as determinants of arterial disease in nine diabetic population samples from the WHO Multinational Study. Diabetes Care 6:361-369, 1983
18. Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H: A prospective study of mortality among middle-aged diabetic patients (the London Cohort of the WHO Multinational Study of Vascular Disease in Diabetics) II: associated risk factors. Diabetologia 33:542-548, 1990
19. Jarrett RJ, Shipley MJ: Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease: putative association via common antecedents: further evidence from the Whitehall Study. Diabetologia 31:737-740, 1988
20. Laakso M, Lehto S, Penttila I, Pyörälä K: Lipids and lipoprotein predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 88:1421-1430, 1993
21. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43:960-967, 1994
22. Klein R: Kelly West Lecture 1994: hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 18:258-268, 1995
23. Klein R, Moss SE, The DCCT Research Group: A comparison of the study populations in the Diabetes Control and Complications Trial and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med 155:745-754, 1995
24. University Group Diabetes Program: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 19 (Suppl. 2):785-930, 1976
25. Seltzer HS: A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 21:976-979, 1972
26. Committee for the Assessment of Biometric Aspects of Controlled Trials of Hypoglycemic Agents: Report of the Committee for the Assessment of Biometric Aspects of Controlled Trials of Hypoglycemic Agents. JAMA 231:583-608, 1975
27. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Henderson W, Comstock JP, Emanuele NV, Levin SR, Pacold I, Lee HS, the Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes (VA CSDM) Group: Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Arch Int Med 157:181-188, 1997
28. UKPDS: UK Prospective Study of Therapies of Maturity-Onset Diabetes. I. Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year. Diabetologia 24: 404-411, 1983
29. Kawamori R, Yamasaki Y, Matsushima H, Nishizawa H, Nao K, Hougaku H, Maeda H, Handa N, Matsumoto M, Kamada T: Prevalence of carotid atherosclerosis in diabetic patients: ultrasound high-resolution B-mode imaging on carotid arteries. Diabetes Care 15:1290-1294, 1992
30. Pujia A, Gnasso A, Irace C, Colonna A, Mattioli PL: Common carotid arterial wall thickness in NIDDM subjects. Diabetes Care 17:1330-1336, 1994
31. Lemp GF, Vander Zwaag R, Hughes JP, Maddock V, Kroetz F, Ramanathan KB, Mirvis DM, Sullivan JM: Association between the severity of diabetes mellitus and coronary arterial atherosclerosis. Am J Cardiol 60:1015-1019, 1987
32. Mykkänen L, Kuusisto J, Pyörälä K, Laakso M: Cardiovascular disease risk factors as predictors of type 2 (non-insulin-dependent) diabetes mellitus in elderly subjects. Diabetologia 36:553-559, 1993
33. Haffner SM, Stern UP, Hazuda HP, Mitchell BD, Patterson JK: Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 263:2893-2898, 1990
34. Reaven GM: 1988 Banting Lecture: role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
35. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP: Prospective analyses of the insulin resistance syndrome (syndrome X). Diabetes 41:715-722, 1992
36. Eschwege E, Richard JL, Thibult N, Ducimetiere P, Warnet JM, Claude JR, Rosselin GE: Coronary heart disease mortality in relation to diabetes, blood glucose and plasma-insulin levels: The Paris Prospective Study, 10 years later. Horm Metab Res 15:41-46, 1985
37. Després JP, Lamarche B, Mauriége P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952-957, 1996
38. Welborn TA, Wearne K: Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 2:154-160, 1979
39. Pyörälä K, Savolainen E, Kaukola S, Haapakoski J: Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive during 9 1/2 year follow-up of the Helsinki Policeman Study population. Acta Med Scand 701:38-52, 1985
40. Orchard TJ, Eichner J, Kuller LH, Becker DJ, McCallum LM, Grandits GA: Insulin as a predictor of coronary heart disease: interaction with apolipoprotein E phenotype: a report from the Multiple Risk Factor Intervention Trial. Ann Epidemiol 4:40-45, 1994
41. Ferrara A, Barrett-Connor E, Edelstein SL: Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: the Rancho Bernardo Study, 1984-1991. Am J Epidemiol 140:857-869, 1994
42. Welin L, Eriksson H, Larsson B, Ohlson LO, Svardsudd K, Tibblin G: Hyperinsulinemia is not a major coronary risk factor in elderly men: the study of men born in 1913. Diabetologia 35:766-770, 1992
43. Rönnemaa T, Laakso M, Pyörälä K, Kallio V, Puukka P: High fasting plasma insulin is an indicator of coronary heart disease in non-insulin dependent diabetic patients and non-diabetic subjects. Arterioscler Thromb 15:80-90, 1991
44. Uusitupa M, Niskanen LK, Siitonen O, Voutilainen E, Pyörälä K: 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin dependent diabetic and non-diabetic subjects. Circulation 82:27-36, 1990
45. Laakso M, Sarlund H, Salonen R, Suhonen M, Pyörälä K, Salonen JT, Karhapää P: Asymptomatic atherosclerosis and insulin resistance. Arterioscler Thromb 11:1068-1076, 1991
46. Bressler P, Bailey SR, Matsuda M, De Fronzo RA: Insulin resistance and coronary artery disease. Diabetologia 39:1345-1350, 1996
47. Howard G, O'Leary DH, Zaccaro D, Haffner SM, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergman R: Insulin sensitivity and atherosclerosis. Circulation 93:1809-1817, 1996
48. Haffner SM, D'Agostino RJ, Saad MF, Rewers M, Mykkänen L, Selby JY Howard G, Savage P, Hamman RF Wagenknecht LE, Bergan RN:. Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Diabetes 45:742-748, 1996
49. Fontbonne A, Eschwege E, Cambien F, Richard JL, Ducimetiere P, Thibult N, Warnet JM, Claude JR, Rosselin GE: Hypertriglyceridemia as a risk factor for coronary heart disease mortality in subjects with impaired glucose tolerance on diabetes: results form the 11 year follow-up of the Paris Prospective Study. Diabetologia 32:300-304, 1989
50. Stamler J, Vacaro O, Neaton O, Wentworth D: Diabetes, other risk factors and 12 year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444, 1993
51. Barrett-Connor E, Grundy SM, Holdbrook JJ: Plasma lipids and diabetes mellitus in an adult community. Am J Epidemiol 115:657-663, 1982
52. Wilson PW, Kannel WB, Anderson KM: Lipids, glucose tolerance and vascular disease: the Framingham Study. Monogr Atheroscler 13:1-11, 1985
53. Ramirez L, Arauz-Pacheco C, Lackner C, Albright G, Adams BV, Raskin P: Lipoprotein(a) levels in diabetes mellitus: relationship to metabolic control. Ann Intern Med 17:42-47, 1992
54. Haffner SM, Morales PA, Stern MP, Gruber KK: Lp(a) concentrations in NIDDM. Diabetes 41:1267-1272, 1992
55. Rainwater DL, MacCleur JW, Stern MP, Vandeberg JL, Haffner SM: Effects of non-insulin dependent diabetes mellitus in Lp(a) concentrations and apolipoprotein(a) size. Diabetes 43:942-946, 1994
56. Haffner SM: Lipoprotein(a) and diabetes. Diabetes Care 16:835-840, 1993
57. Austin MA, Breslow JL, Hennekens CHD, Buring JE, Willett WC, Krauss RM: Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260:1917-1921, 1988
58. Barakat HA, Carpenter JW, McLendon VD, Khazanie P, Leggett N, Heath J, Marks R: Influence of obesity, impaired glucose tolerance and NIDDM on LDL structure and composition: possible link between hyperinsulinemia and atherosclerosis. Diabetes 39:1527-1533, 1990
59. Haffner SM, Mykkänen L, Valdez RA, Paidi M, Stern MP, Howard BV: LDL size and subclass pattern in a biethnic population. Arteriosclerosis 13:1623-1630, 1993
60. Selby JV, Austin MA, Newman B, Zhang D, Quesenberry CP, Mayer EJ, Krauss RM: LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation 85:381-387, 1993
61. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM: Insulin resistance in individuals with small, dense lipoprotein particles. J Clin Invest 92:141-146, 1993
62. McNamara JR, Campos H, Ordovas JM, Peterson RM, Wilson PW, Schaefer EJ: Effect of gender, age and lipid status on low density subfraction distribution: results of the Framingham Offspring Study. Arteriosclerosis 7:483-490, 1987
63. Feingold KR, Grunfeld C, Doerrler W, Krauss RM: LDL subclass phenotypes and triglyceride metabolism in non-insulin dependent diabetes. Arterioscler Thromb 12:1496-1502, 1992
64. Haffner SM, Mykkänen L, Stern MP, Paidi M, Howard BV: Greater effect of diabetes on LDL size in women than in men. Diabetes Care 17:1164-1171, 1994
65. Caixàs A, Ordóñmez-Llanos J, de Leiva A, Payés A, Homs R, Pérez A: Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL patients in diabetic patients. Diabetes 46:1207-1213, 1997
66. Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications. Diabetes Care 19:257-267, 1996
67. Chisolm GM, Irwin KC, Penn MS: Lipoprotein oxidation and lipoprotein-induced cell injury in diabetes. Diabetes 41 (Suppl. 2):61-66, 1992
68. Lyons TJ: Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol 71:26B-31B, 1993
69. Berliner JA, Territo M, Navab M, Andalibi A, Parhami F, Liao F, Kim J, Estworthy S, Lusis AJ, Fogelman AM: Minimally modified lipoproteins in diabetes. Diabetes 41 (Suppl. 2):74-76, 1992
70. Witztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 88:1785-1792, 1991
71. Bowie A, Owens D, Collins P, Johnson A, Tomkin GH: Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? Atherosclerosis 102:63-67, 1993
72. Sato Y, Hotta N, Sakamoto N, Matsuoka S, Ohishi N, Yagi K: Lipid peroxide level in plasma of diabetic patients. Biochem Med 21:104-107, 1979
73. Haffner SM, Agil A, Mykkänen L, Stern MP, Jialal I: Plasma oxidizability in subjects with normal glucose tolerance, impaired glucose tolerance and NIDDM. Diabetes Care 18:646-653, 1995
74. Stampfer MJ, Hennekens CHD, Manson JE, Colditz GA, Rosner B, Willett WC: Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 328:1444-1449, 1993
75. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC: Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 328:1450-1456, 1993
76. Morel DW, Chisolm GM: Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity. J Lipid Res 30:1827-1834, 1989
77. Ceriello A, Guigliano D, Quatraro A, Donzella C, Diplao G, Lefebvre PJ: Vitamin E reduction of protein glycosylation in diabetes: new prospect for prevention of diabetic complications? Diabetes Care 14:68-72, 1991
78. Reaven PD, Herold DA, Barnett J, Edelman S: Effects of vitamin E on susceptibility of low-density lipoprotein and low-density lipoprotein subtractions to oxidation and on protein glycation in NIDDM. Diabetes Care 18:807-816, 1995
79. Paolisso G, d'Amore A, Galzzerano D, Balbi V, Giugliano D, Varricchio M, D'Onofrio F: Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type 2 diabetic patients. Diabetes Care 16:1433-1437, 1993
80. Ginsberg H: Lipoprotein physiology in non-diabetic and diabetic states: relationship to atherogenesis. Diabetes Care 14:839-855, 1991
81. Briones ER, Mao SJ, Palumbo PJ, O'Fallon WM, Chenoweth W, Kottke BA: Analysis of plasma lipids and apolipoproteins in insulin-dependent and non-insulin dependent diabetes. Metabolism 33:42-49, 1984
82. Stern MP, Mitchell BD, Haffner SM, Hazuda HP: Does glycemic control of type 2 diabetes suffice to control diabetic dyslipidemia? a community perspective. Diafeetes Care 15:638-644, 1992
83. Kissebah AH, Alfarsi S, Evans DJ, Adams PW: Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes 31:217-225, 1982
84. Ginsberg H, Grundy SM: Very low density lipoprotein metabolism in non-ketotic diabetes mellitus: effect of dietary restriction. Diobetologia 23:421-425, 1982
85. Taskinen M-R, Packard CJ, Shepherd J: Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM. Diabetes 39:1017-1027, 1990
86. Taskinen M-R, Beltz WF, Harper I, Fields RM, Schonfeld G, Grundy SM, Howard BV: Effects of NIDDM on very-low-density lipoprotein triglyceride and apolipoprotein B metabolism: studies before and after sulfonylurea therapy. Diabetes 35:1268-1277, 1986
87. Dunn FL, Raskin P, Billheimer DW Grundy SM: The effect of diabetic control on very low-density lipoprotein-triglyceride metabolism in patients with type 2 diabetes mellitus and marked hypertriglyceridemia. Metabolism 33:117-123, 1984
88. Brunzell JD, Porte DJ, Bierman EL: Abnormal lipoprotein-lipase-mediated plasma triglyceride removal in untreated diabetes mellitus associated with hypertriglycendemia. Metabolism 28:901-907, 1979
89. James R, Pometta D: The distribution profiles of very low density and low density lipoproteins in poorly-controlled male, type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34:246-252, 1991
90. Bagdade JD, Buchanan WE, Kuusi T, Taskinen MR: Persistent abnormalities in lipoprotein composition in non-insulin-dependent diabetes after intensive insulin therapy Arteriosclerosis 10:232-239, 1990
91. Kraemer FB, Chen YC, Lopez RD, Reaven GM: Effects of non-insulin-dependent diabetes mellitus on the uptake of very low density lipoproteins by thioglycolateelicted mouse peritoneal macrophages. J Clin Endocrinol Metab 61:335-342, 1985
92. Golay A, Zech L, Shi MZ, Chiou YA, Reaven GM, Chen YD: High-density lipoprotein (HDL) metabolism in non-insulin-dependent diabetes mellitus: measurement of HDL turnover using tritiated HDL. J Clin Endocrinol Metab 65:512-518, 1987
93. Biesbroeck RC, Albers JJ, Wahl PW, Weinberg CR, Bassett ML, Bierman EL: Abnormal composition of high density lipoproteins in non-insulin-dependent diabetics. Diabetes 31:126-131, 1982
94. Lane J, Subbaiah P, Otto M: Lipoprotein composition and HDL particle distributions in women with non-insulin dependent diabetes mellitus and the effect of probucol treatment. J Lab Clin Med 118:120-128, 1991
95. Kissebah AH, Alfarsi S, Evans DJ, Adams PW: Plasma low density lipoprotein transport kinetics in non-insulin-dependent diabetes mellitus. J Clin Invest 71:655-667, 1983
96. Witztum JL, Mahoney EM, Branks MJ, Fisher M, Elam RL, Steinberg D: Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity Diabetes 31:283-291, 1982
97. Witztum JL, Fisher M, Pietro T, Steinbrecher UP, Elam RL: Nonenzymatic glucosylation of high density lipoprotein accelerates its catabolism in guinea pigs. Diabetes 31:1029-1032, 1982
98. Chait A, Bierman EL, Albers JJ: Low density lipoprotein receptor activity in cultured human skin fibroblasts: mechanism of insulin-induced stimulation. J Clin Invest 64:1309-1319, 1979
99. Fielding CJ, Reaven GM, Fielding PE: Human noninsulin-dependent diabetes: identification of a defect in plasma cholesterol transport normalized in vivo by insulin and in vitro by selective immunoabsorption of apolipoprotein E. Proc Natl Acad Sci USA 79:6365-6369, 1982
100. Fielding CJ, Reaven GM, Liu G, Fielding PE: Increased free cholesterol in plasma low and very low density lipoproteins in non-insulin-dependent diabetes mellitus: its role in the inhibition of cholesteryl ester transfer. Proc Natl Acad Sci USA 81:2512-2516, 1984
101. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, Tyroler HA: Tenyear mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 322:1700-1707, 1990
102. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Study (4S). Lancet 344:1383-1389, 1994
103. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW Arnold JM, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 335:1001-1009, 1996
104. Pyörälä K, Pedersen TR, Kjeksus J, Faergerman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620, 1997
105. Tonkin AM for the LIPID study group: Management of the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study after the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 76:107 C-112C, 1995
106. Goldbourt U, Behar S, Reicher-Reiss H, Agmon J, Kaplinsky E, Graff E, Kishon Y, Caspi A, Weisbort J, Mandelzweig L: Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol 71:909-915, 1993
107. Pyörälä K, Steiner G: Will correlation of dyslipoproteinaemia reduce coronary heart disease risk in patients with non-insulin-dependent diabetes? need for trial evidence. Ann Med 28:357-362, 1996
108. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male post infarction patients. Lancet 347:849-853, 1996
109. Steiner G for the DAIS Project Group: The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. Diabetologia 39:1655-1661, 1996
110. Abbot RD, Donahue KP, Kannel WB, Wilson PW: The impact of diabetes on survival following myocardial infarction in men vs. women: the Framingham Study JAMA 260:3456-3460, 1988
111. Herliz J, Karlson BW, Edvardsson N, Emanuelsson H, Hjalmarson Å: Prognosis in diabetics with chest pain or other symptoms suggestive of acute myocardial infarction. Cardiology 80:237-245, 1992
112. Miettinen H, Lehto S, Salomaa VV, Mähönen M, Niemalä M, Haffner SM, Pyörälä K, Tuomilehto J: Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 21:69-75, 1998
113. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Jacfarlane PW McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301-1307, 1995
114. Medical Research Council/British Heart Foundation Heart Protection Study: a randomized study of the effects on mortality and morbidity of HMG CoA reductase inhibitors and of antioxidant vitamin in a wide range of people at high risk of coronary heart disease. Protocol. Oxford, Heart Protection Study, 1994
115. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 85:37-45, 1992
116. Koskinen P, Mänttäri M, Manninen V, Huttunen JK, Heinonen OP, Frick MH: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 15:820-825, 1992
117. Heinonen OP, Huttunen JK, Manninen V, Mänttari M, Koskinen P, Tenkanen L, Frick MH: The Helsinki Heart Study: coronary heart disease incidence during an extended follow-up. J Int Med 235:41-49, 1994
118. NCEP Expert Panel: Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol (Adult Treatment Panel II): expert panel on detection, evaluation and treatment of high load cholesterol. JAMA 209:3015-3023, 1993
119. The Post Coronary Artery Bypass Graft Trial Investigators: The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 336:153-162, 1997
120. Kroon AA, van Asten WNJC, Stalenhoef AFH: Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med 125:945-954, 1996
121. Pedersen TR, Kjekshus J, Berg K, Olsson AG, Wilhelmsen L, Wedel H, Pyörälä K, Miettinen T, Haghfelt T, Faergeman O, Thorgeirsson G, Jönsson B, Schwartz JS, for the Scandinavian Simvastatin Survival Study Group: Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation 93:1796-1802, 1996
122. Johannesson M, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H, for the Scandinavian Simvastatin Survival Study Group: Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 336:332-336, 1997
123. American Diabetes Association: Nutrition recommendation and principles for people with diabetes mellitus. (Position Statement). Diabetes Care 21 (Suppl. 1):S32-S35, 1998
124. Franz MJ, Horton ES, Bantle JP, Beebe CA, Brunzell JD, Coulston AM, Henry RR, Hoogwerf BJ, Stacpoole PW: Nutrition principles for the management of diabetes and related complications. Diabetes Care 17:490-518, 1994
125. Garg A, Bonanome A, Grundy SM, Zhang AJ, Unger RH: Comparison of a high-carbohydrate diet with high monosaturated-fat diet in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 391:829-834, 1988
126. Coulston AM, Hollenbeck CB, Swislock ALM, Reaven GM: Persistence of hypertriglyceridemic effect of low fat, high carbohydrate diets in NIDDM patients. Diabetes Care 12:94-101, 1989
127. Garg, A, Grundy SM, Koffler M: Effect of high carbohydrate intake on hyperglycemia, islet function, and plasma lipoproteins in NIDDM. Diabetes Care 15:1572-1580, 1992
128. Garg A, Bantle JP, Henry RR, Coulston AM, Griver KA, Raatz SK, Brinkley L, Chen YD, Grundy SM, Huet BA, Reaven GM: Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. JAMA 271:1421-1428, 1994
129. Howard BV, Abbott WGH, Swinburn BA: Evaluation of metabolic effects of substitution of complex carbohydrates for saturated fat in individuals with obesity and NIDDM. Diabetes Care 14:786-795, 1991
130. Milne RM, Mann JI, Chisholm AW, Williams SM: Long-term comparison of three dietary prescriptions in the treatment of NIDDM. Diabetes Care 17:74-80, 1994
131. Grundy SM: Dietary therapy in diabetes mellitus: is there a single best diet? Diabetes Care 14:796-780, 1991
132. Monk A, Barry B, McClain K, Weaver T, Cooper N, Franz MJ: Practice guidelines for medical nutrition therapy provided by dietitians for persons with non-insulin dependent diabetes mellitus. J Am Diet Assoc 95:999-1006, 1995
133. American Diabetes Association: Diabetes and exercise (Position Statement). Diabetes Care 201 (Suppl. 1):S51, 1997
134. Schneider SH, Ruderman NB: Exercise and NIDDM (Technical Review). Diabetes Care 13:785-789, 1990
135. Wasserman DH, Zinman B: Exercise in individuals with IDDM (Technical Review). Diabetes Care 17:924-937, 1994
136. Pate RR, Pratt M, Blair SN, Haskell WL, Macera CA, Bouchard C, Buchner D, Ettinger W, Heath GW, King AC, Kriska A, Leon AS, Marcus BH, Morris J, Paffenbarger RS Jr, Patrick K, Pollock ML, Rippe JM, Sallis J, Wilmore JH: Physical activity and public health: a recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 273:402-407, 1995
137. Garg A: Management of dyslipidemia in IDDM patients. Diabetes Care 17:224-234, 1994
138. Garg A, Grundy SM: Management of dyslipidemia in NIDDM. Diabetes Care 13:153-159, 1990
139. Garber AJ, Vinik AI, Crespin SR: Detection and management of lipid disorders in diabetic patients: a commentary for clinicians. Diabetes Care 15:1068-1074, 1992
140. Stern MP, Haffner SM: Dyslipidemia in type 2 diabetes: implications for therapeutic intervention. Diabetes Care 14:1144-1159, 1991
141. American Diabetes Association: The pharmacological treatment of hyperglycemia in NIDDM (Consensus Statement). Diabetes Care 18:1510-1518, 1995
142. Yki-Jarvinen H, Kauppila M, Kujansuu E, LahtiJ, Marjanen T, Niskanen LK, Rajala S, Ryysy L, Salo S, Seppala P: Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 327:1426-1433, 1992
143. DeFronzo RA, Goodman AM, Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. N Engl J Med 333:541-549, 1995
144. Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TM: The efficacy of acarbose in treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med 121:928-935, 1994
145. Liu GC, Coulston AM, Lardinois CK, Hollenbeck CB, Moore JG, Reaven GM: Moderate weight loss and sulfonylurea treatment of non-insulin-dependent diabetes mellitus. Arch Intern Med 145:665-669, 1985
146. Bergman M, Gidez LI, Eder HA: The effect of glipizide on HDL and HDL subclasses. Diabetes Res 3:245-248, 1986
147. Greenfield M, Doberne L, Rosenthal M, Vreman HJ, Reaven GM: Lipid metabolism in non-insulin-dependent diabetes mellitus: effect of glipizide therapy Arch Intern Med 142:1498-1500, 1982
148. Agardh CD, Nilsson-Ehle P, Scherstén B: Improvement of the plasma lipoprotein pattern after institution of insulin treatment in diabetes mellitus. Diabetes Care 5:322-325, 1982
149. Hollenbeck CB, Chen YD, Greenfield M, Lardinois CK, Reaven GM: Reduced plasma high density lipoprotein-cholesterol concentrations need not increase when hyperglycemia is controlled with insulin in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 62:605-608, 1986
150. Taskinen M-R, Kuusi T, Helve E, Nikkila EA, Uki Jarvinen H: Insulin therapy induces anti-atherogenic changes of serum lipoproteins in non-insulin-dependent diabetes. Arteriosclerosis 8:168-177, 1988
151. Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, Fücker K: Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 14:732-737, 1991
152. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T: Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 19:151-156, 1996
153. Mahmoud NG, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, The Troglitazone Study Group, Whitcomb RW: Cardiac and glycemic benefits of troglitozone treatment in NIDDM. Diabetes 46:433-439, 1997
154. Lopes-Virella MFL, Stone PG, Colwell JA: Serum high density lipoprotein in diabetic patients. Diabetologia 13:285-291, 1977
155. Paisey R, Elkeles RS, Hambley J, Magill P: The effects of chlorpropamide and insulin on serum lipids, lipoproteins and fractional triglyceride removal. Diabetologia 15:81-85, 1978
156. Rabkin SW, Boyko E, Streja DA: Changes in high density lipoprotein cholesterol after initiation of insulin therapy in non-insulin-dependent diabetes mellitus: relationship to changes in body weight. Am J Med Sci 285:14-20, 1983
157. Chen YD, Jeng CY, Reaven GM: HDL metabolism in diabetes. Diabetes Metab Rev 3:653-668, 1987
158. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS: Veterans Administration Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM): results of the feasibility trial: Veterans Administration Cooperative Study in Type II Diabetes. Diabetes Care 18:1113-1123, 1995
159. Diabetes Control and Complications Trial Research Group: Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 75:894-903, 1995
160. Kesaniemi YA, Grundy SM: Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. JAMA 251:2241-2246, 1984
161. Garg A, Grundy SM: Gemfibrozil alone and in combination with lovastatin for the treatment of hypertriglyceridemia in NIDDM. Diabetes 38:364-372, 1989
162. Vinik AI, Colwell JA: Hyperlipidemia in Diabetes Investigator Study Diabetes Care 16:37-44, 1993
163. Lahdenperä S, Tilly-Kiesi M, Vuorinen-Markkola H, Kuusi T, Taskinen MR: Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type 2 diabetes. Diabetes Care 16:584-592, 1993
164. Vega G, Grundy SM: Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease: effects on metabolism on low-density lipoproteins. JAMA 253:2398-2403, 1985
165. Jones IR, Swai A, Taylor R, Miller M, Laker MF, Alberti KG: Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM. Diabetes Care 13:855-863, 1990
166. Crouse JR: Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am J Med 83:243-248, 1987
167. Garg A, Grundy SM: Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus: a short-term, double-blind, crossover trial. Ann Intern Med 121:416-422, 1994
168. Carlson LA, Hamsten A, Aspland A: Pronounced lowering of serum levels of Lp(a) in hyperlipidemic subjects with nicotinic acid. J Intern Med 226:271-276, 1989
169. Garg A, Grundy SM: Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 264:723-726, 1990
170. Kahn SE, Beard JC, Schwartz MW, Ward WK, Ding HL, Bergman RN, Taborsky GJJ, Porte DJ: Increased β-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 38:562-568, 1989
171. Carlson LA, Oro L: The effect of nicotinic acid on the plasma free fatty acids. Acta Med Scand 172:641-645, 1962
172. Fuccella LM, Goldaniga G, Lovisolo P, Maggi E, Musatti L, Mandelli V, Sirtori CR: Inhibition of lipolysis by nicotinic acid and by acipimox. Clin Pharmacol Ther 28:790-795, 1980
173. Fulcher GR, Walker M, Catalano C, Alberti KG: Overnight suppression of lipolysis with acipimox increases carbohydrate oxidation and lowers fasting blood glucose in type 2 diabetes. Diabetologia 32:489A, 1989
174. Henkin Y, Segrest JP: Nicotinic acid in NIDDM (Letter). JAMA 264:2994-2995, 1994
175. Schectman G, Hiatt J: Dose response characteristics of cholesterol-lowering drug therapies: implications for treatment. Ann Intern Med 125:990-1000, 1996
176. Rader JI, Calvert RJ, Hathcock JN: Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 92:77-81, 1992
177. Garg A, Grundy SM: Lovastatin for lowering cholesterol levels in non-insulin dependent diabetes mellitus. N Engl J Med 318:81-86, 1988
178. Raskin P, Ganda OP, Schwartz S, Willard D, Rosenstock J, Lodewick PA, Cressman MD, Phillipson B, Weiner B, McGovern ME: Efficacy and safety of pravastatin in the treatment of patients with type 1 or type 2 diabetes mellitus and hypercholesterolemia. Am J Med 99:362-369, 1995
179. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM: Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 15:678-682, 1995
180. Heinonen T, Stein E, Isaacsohn J, Davidson M, Davignon J, Montigny M, Tremblay G, Edwards A, Hunninghake D, Ooi T, Schrott H, Knopp R, Lupien PJ, Gagne C, McKenney J, Zavoral J, Sniderman A, Frohlich I, Leiter L, McQueen M, Steiner G, Gauder D, Keilson L, Dujovac C, McLain R, Black D: Atorvastatin monotherapy in the treatment of severe hypercholesterolemia (Abstract). In Abstracts of the European Atherosclerosis Society 66th Annual Meeting, Florence, Italy, July 1996, p. 214
181. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM: Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 275:128-133, 1996
182. Nawrocki J, Schwartz S, Fayyad R, Simunovic L: Atorvastatin, a new HMG-CoA reductase inhibitor is safe and effective in patients with diabetes. Presented at the 66th Congress European Atherosclerosis Society Meeting, Florence, Italy, July 13-17, 1996
183. Davidson MH, Stein EA, Dujovne CA, Hunnihnhake DB, Weiss SR, Knopp RH, Illingworth DR, Mitchel YB, Melino MR, Zupkis RV, Dobrinska MR, Amin RD, Toben JA: The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 79:38-42, 1997
184. Pierce LR, Wysowski DK, Gross TP: Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 264:71, 1990
185. Glueck CJ, Oakes N, Speirs J, Tracy T, Lang J: Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. Am J Cardiol 70:1-9, 1992
186. Hutchesson AC, Moran A, Jones AF: Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia. J Clin Pharm Ther 19:387-389, 1994
187. Magarian FJ, Lucas LM, Colley C: Gemfibrozil-induced myopathy. Arch Intern Med 151:1873-1874, 1991
188. Dujovne CA, Chremos AN, Pool JL, Schnaper H, Bradford RH, Shear CL, Higgins J, Downton M, Franklin FA, Nash DT: Expanded clinical evaluation of lovastatin (EXCEL) study results. IV. Additional perspectives on the tolerability of lovastatin. Am J Med 91:25S-30S, 1991
189. Wiklund O, Bergman M, Bondjers G, Lindén T, Ödman B, Saarinen I, Kron B, Wright I: Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 94:13-20, 1993
190. Decoulx E, Millaire A, de Groote P, Mahieux G, Ducloux G: Rhabdomyolysis caused by pravastatin and type 1 macrocreatinine kinase. Ann Cardiol Angeiol (Paris) 42:267-269, 1993
191. Stein EA, Davidson MH, Dujovne CA, Hunninghake DB, Goldberg RB, Illingworth R, Knopp RH, Miller VT, Frost P, Isaacsohn JL, Mitchel YB, Melino MR, Shapiro D, Tobert JA: Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: a prospective trial. J Cardiovasc Pharmacol Therapeut 1:107-116, 1996
192. Davignon J, Roederer G, Montigny M, Hayden MR, Tan MH, Connelly PW: Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol 73:339-345, 1994
193. American Diabetes Association: Management of dyslipidemia in adults with diabetes (Position Statement). Diabetes Care 21:179-182, 1998
194. Friedewald WT, Levy RI, Frederickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
195. Warnick GR, Knopp RH, Fitzpatrick V, Bronson L: Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem 36:15-19, 1990
196. Senti M, Pedro-Botet J, Nogues X, Rubies-Prat J: Influence of intermediate-density lipoproteins on the accuracy of the Friedewald formula. Clin Chem 37:1394-1397, 1991
197. McNamara JR, Cohn JS, Wilson PWF, Schaefer EJ: Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. Clin Chem 36:36-42, 1990
198. Bacharik PS, Ross JW, for the NCEP Working Group on Lipoprotein Measurement: National Cholesterol Education Program recommendations for measurement of lowdensity lipoprotein cholesterol: executive summary. Clin Chem 41:1414-1420, 1995
199. Rubies-Prat J, Reverter JL, Senti M, Pedro-Botet J, Salinas I, Lucas A, Nogues X, Sanmarti A: Calculated low-density lipoprotein cholesterol should not be used for management of lipoprotein abnormalities in patients with diabetes mellitus. Diabetes Care 16:1081-1086, 1993
200. Whiting MJ, Shephard MDS, Tallis GA: Measurement of plasma LDL cholesterol in patients with diabetes. Diabetes Care 20:12-14, 1997
201. McNamara JR, Cole TG, Contois JH, Ferguson CA, Ordovas JM, Schaefer EJ: Immuno-separation method for measuring low-density lipoprotein cholesterol directly from serum evaluated. Clin Chem 41:232-240, 1995
202. Hirany S, Li D, Jialal I: A more valid measurement of low density lipoprotein cholesterol in diabetic patients. Am J Med 102:48-53, 1997
203. Havel RJ, Rapoport E: Management of primary hyperlipidemia. N Engl J Med 33:1497-1498, 1996
204. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Decken T: Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia 30:144-148, 1987
205. Lounamaa P, Lounamaa R, Tuomilehto J, Reunanen A: Mortality of type 1 diabetes: the relative risk is higher in females but the absolute increased risk is higher in males (Abstract). Diabetologia 34:A178, 1991
206. Krolewski AS, Kosinski EJ, Warram JH, Leland OS, Busick EJ, Asmal AC, Rand LI, Christlieb AR, Bradley RF, Kahn CR: Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 59:750-755, 1987
207. Maser RE, Wolfson SK Jr, Ellis D, Stein EA, Drash AL, Becker DJ, Dorman JS, Orchard TJ: Cardiovascular disease and arterial calcification in insulin-dependent diabetes mellitus: interrelations and risk factor profiles: Pittsburgh Epidemiology of Diabetes Complications Study-V. Arterioscler Thromb 11:958-965, 1991
208. Laakso M, Pyörälä K, Sarlund H, Voutilainen E: Lipid and lipoprotein abnormalities associated with coronary heart disease in patients with insulin-dependent diabetes mellitus. Arteriosclerosis 6:679-684, 1986
209. Lloyd CE, Kuller LH, Ellis D, Becker DJ, Wing RR, Orchard TJ: Coronary artery disease in IDDM: gender differences in risk factors but not risk. Arterioscler Thromb Vasc Bio 16:720-726, 1996
210. Zinman B, Cleary P, O'Leary D, Orchard T for the EDIC study group: The effect of intensive diabetes treatment of carotid artery wall thickness in the epidemiology of diabetes interventions and complications (Abstract). Diabetes 45 (Suppl. 2):188A, 1996
211. Klein BE, Moss SE, Klein R, Surawicz TS: Serum cholesterol in Wisconsin epidemiologic study of diabetic retinopathy. Diabetes Care 15:282-287, 1992
212. The DCCT Research Group: Lipid and lipoprotein levels in patients with IDDM diabetes control and complication: trial experience. Diabetes Care 15:886-894, 1992
213. Winocour PH, Durrington PN, Ishola M, Millier VF, Anderson DC: The prevalence of hyperlipidemia and related clinical features in insulin-dependent diabetes mellitus. Q J Med 70:265-276, 1989
214. Sosenko JM, Breslow JL, Miettinen OS, Gabbay KH: Hyperglycemia and plasma lipid levels: a prospective study of young insulin-dependent diabetic patients. N Engl J Med 302:650-654, 1980
215. Walden CE, Knopp RH, Wahl PW, Beach KW, Strandness E Jr: Sex differences in the effect of diabetes mellitus on lipoprotein triglyceride and cholesterol concentrations. N Engl J Med 311:953-959, 1984
216. Bagdade JD, Porte D, Bierman EL: Diabetic lipemia: a form of acquired fat-induced lipemia. N Engl J Med 276:427-433, 1967
217. Pietri A, Dunn FL, Raskin P: The effect of improved diabetic control on plasma lipid and lipoprotein levels: a comparison of conventional therapy and continuous subcutaneous insulin infusion. Diabetes 29:1001-1005, 1980
218. Dunn FL, Pietr A, Raskin P: Plasma lipid and lipoprotein levels with continuous subcutaneous insulin infusion in type 1 diabetes mellitus. Ann Intern Med 95:426-431, 1981
219. Sánchez-Quesada JL, Pérez A, Caixas A, Ordóñmez-Llanos J, Carreras, G, Payes A, Gonzalez-Sastre F, de Leiva A: Electronegative low density lipoprotein subform is increased in patients with short-duration IDDM and is closely related to glycaemic control. Diabetologia 39:1469-1476, 1996
220. Purnell JQ, Marcovina SM, Hokanson JE, Kennedy H, Cleary PA, Steffes MW, Brunzell JD: Levels of lipoprotein (a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM: results from follow-up in the Diabetes Control and Complications Trial. Diabetes 44:1218-1226, 1995
221. Tsai EC, Hirsch IB, Brunzell JD, Chait A: Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 43:1010-1014, 1994
222. Jenkins AJ, Klein RL, Chassereau CN, Hermayer KL, Lopes-Virella MF: LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation. Diabetes 45:762-767, 1996
223. Pietri AO, Dunn FL, Grundy SM, Raskin P: The effect of continuous subcutaneous insulin infusion on very-low-density lipoprotein triglyceride metabolism in type 1 diabetes mellitus. Diabetes 32:75-81, 1983
224. Rivellese A, Riccardi G, Romano G, Giacco R, Patti L, Marotta G, Annuzzi G, Mancini M: Presence of very-low-density lipoprotein compositional abnormalities in type 1 (insulin-dependent) diabetic patients: effects of blood glucose optimisation. Diabetologia 31:884-888, 1988
225. Bagdade JD, Subbaiah PV: Whole-plasma and high-density lipoprotein subfraction surface lipid composition in IDDM men. Diabetes 38:1226-1230, 1989
226. Bagdade JD, Helve E, Taskinen MR: Effects of continuous insulin infusion therapy on lipoprotein surface and core lipid composition in insulin-dependent diabetes mellitus. Metabolism 40:445-449, 1991
227. Nikkila EA, Hormila P: Serum lipids and lipoproteins in insulin-treated diabetes: demonstration of increased high-density lipoprotein concentrations. Diabetes 27:1078-1086, 1978
228. Eckel RH, Albers JJ, Cheung MC, Wahl PW, Lindgren FT, Bierman EL: High-density lipoprotein composition in insulin-dependent diabetes mellitus. Diabetes 30:132-138, 1981
229. Mattock MB, Salter AM, Fuller JH, Omer T, R-El-Gohari, Redmond SD, Keen H: High-density lipoprotein subfractions in insulin-dependent diabetic and normal subjects. Atherosclerosis 45:67-79, 1982
230. Brunzell JD, Porte D Jr, Bierman EL: Abnormal lipoprotein-lipase-mediated plasma triglyceride removal in untreated diabetes mellitus associated with hypertriglyceridemia. Metabolism 28:901-907, 1979
231. Rosenstock J, Vega GL, Raskin P: Effect of intensive diabetes treatment on low-density lipoprotein apolipoprotein B kinetics in type I diabetes. Diabetes 37:393-397, 1988
232. Laakso M, Pyörälä K: Adverse effects of obesity on lipid and lipoprotein levels in insulin-dependent and non-insulin-dependent diabetes. Metabolism 39:117-122, 1990
233. Stuhldreher WL, Orchard TJ, Ellis D: The association of waist-hip ratio and risk factors for development of IDDM complication in an IDDM adult population. Diabetes Res Clin Prac 17:99-109, 1992
234. Kjaer K, Hangaard J, Petersen NE, Hagen C: Effect of simvastatin in patients with type 1 (insulin-dependent) diabetes mellitus and hypercholesterolemia. Acta Endocrinol 126:229-232, 1992
235. Hommel E, Andersen P, Gall MA, Nielsen F, Jensen B, Rossing P, Dyerberg J, Parving HH: Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia 35:447-451, 1992